Funder: National Institutes of Health
Due Date: 10/15/2018
The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.
The R61/R33 FOAs are intended to support biphasic high risk applications. Support for a single phased award that does not need the developmental (R61) phase is available in the companion FOA, RFA-MH-18-703.